Rocket Pharmaceuticals Reports Q2 2025 Results; No Significant Variations in Sales, Net Income, or EPS Announced
Reuters
Aug 08
Rocket Pharmaceuticals Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Results; No Significant Variations in Sales, Net Income, or EPS Announced
Rocket Pharmaceuticals Inc. announced their financial results for the second quarter of 2025, revealing a net loss of $68.9 million or $0.62 per share for the three months ending June 30, 2025. This compares to a net loss of $69.6 million or $0.74 per share for the same period in 2024. The company also reported having $271.5 million in cash, cash equivalents, and investments, which is expected to support operations until the second quarter of 2027. In response to market dynamics, Rocket Pharmaceuticals is implementing an organizational restructuring, which includes a 30% reduction in headcount and is anticipated to lower the company's 12-month cash burn by approximately 25%. Restructuring and related charges amounted to about $3.5 million in the first half of 2025. The company is shifting its strategic focus towards its AAV cardiovascular gene therapy platform. Key developments include FDA RMAT designation for RP-A601 in PKP2-ACM and the acceptance of an IND with a Fast Track designation for RP-A701 in the BAG3-DCM program. The company is pausing further investments in FA and PKD programs while exploring external strategic alternatives for them. Chris Stevens has been appointed as the new Chief Operating Officer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rocket Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250807231064) on August 07, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.